BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Bocxman,

I believe they did do this independent test but the expensive independent tests don't seem to get the public very excited. Until Abbott releases approval + FDA follows suite, we are in a holding pattern. Many tests have been performed with great results but it was Abbott's anouncement that moved the stock.

The presentation includes a comparison, cancer by cancer, of the data obtained by BioCurex with data obtained in a blind study by an external independent research group. In one case (benign breast tumors vs. cancer) the results from the blind test were slightly lower than ours but yet very significant, whereas in most other cases, the results obtained with the blind samples were similar or even better than our own -- such as with breast cancers vs. normal individuals, in which the RECAF blind test achieved 100% Sensitivity with 100% Specificity on the 43 cancer and 50 normal samples sent by the independent scientists.

The talk included diagnostic test results on tissue sections and blood samples, as well as preliminary results on the therapeutic applications demonstrating that RECAF technology can be used to kill 100% of cancer cells in culture without killing a significant number of normal cells.
http://72.14.207.104/search?q=cache:gyb2KOx1chcJ:biz.yahoo.com/pz/051114/89764.html+biocurex+indepen...